Endpoints article on Inclisiran | ALNY Message Board Posts

Alnylam Pharmaceuticals

  ALNY website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34755 of 34847  at  1/14/2020 9:51:34 AM  by

Steve_382


Endpoints article on Inclisiran

 I have been saying this for a while, but I still think Inclisiran may be a big deal. I also  hope to be using it as soon as it's approved, but that's another story.
 
 
January 14, 2020 08:21 AM EST
Natalie Grover

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

It may not have yet se­cured ap­proval, nor re­viewed by UK’s price-ef­fec­tive­ness watch­dog NICE — but the cho­les­terol ther­a­py in­clisir­an at the heart of last year’s No­var­tis $9.7 bil­lion buy­out of the Med­i­cines Com­pa­ny will be made wide­ly avail­able to pa­tients at risk of heart dis­ease in the Na­tion­al Health Ser­vice (NHS), the UK agency said on Mon­day.

NHS Eng­land will agree to a pop­u­la­tion-lev­el com­mer­cial arrange­ment with No­var­tis to make it wide­ly avail­able to pa­tients as soon as 2021 — in ad­di­tion, the bian­nu­al shot will al­so be test­ed in UK pa­tients as part of a large-scale NHS clin­i­cal tri­al ex­pect­ed to start lat­er this year.

“Ear­ly re­sults from clin­i­cal tri­als sug­gest that if in­clisir­an is giv­en to 300,000 pa­tients an­nu­al­ly, it could help pre­vent 55,000 heart at­tacks and strokes, and has the po­ten­tial of sav­ing 30,000 lives in the next 10 years,” the NHS said, high­light­ing that re­cent tri­als have shown in­clisir­an can halve bad cho­les­terol in two weeks.

advertisementadvertisement

De­spite the wide adop­tion of statins, such as Pfiz­er’s $PFE near­ly $13 bil­lion-at-peak Lip­i­tor, hy­per­c­ho­les­terolemia and as­so­ci­at­ed car­dio­vas­cu­lar dis­ease is a lead­ing glob­al killer, rep­re­sent­ing fer­tile ground for fresh, po­tent ther­a­pies to reap lu­cra­tive re­turns. In the UK, heart dis­ease is the sec­ond biggest cause of death.

The cho­les­terol-low­er­ing Repatha from Am­gen, and ri­val Pralu­ent from Re­gen­eron and Sanofi, were ap­proved in the Unit­ed States in 2015 in post-statin pa­tients amidst much fan­fare — their mak­ers flush with block­buster ex­pec­ta­tions. In­stead, they faced in­sur­er push­back for their high stick­er prices ($14,000) that led to low­er-than-ex­pect­ed adop­tion. Lat­er, tri­als demon­strat­ed the PC­SK9 in­hibitors al­so sig­nif­i­cant­ly cut car­dio­vas­cu­lar risk — da­ta that are now re­flect­ed on their la­bels — as well as safe use in re­nal­ly-im­paired pa­tients, but their man­u­fac­tur­ers end­ed up cut­ting their prices by 60%, in a bid to boost tepid sales.

Un­like Repatha and Pralu­ent — which work by in­hibit­ing the PC­SK9 pro­tein and there­by di­min­ish­ing LDL-C or “bad” cho­les­terol — in­clisir­an is a siR­NA ther­a­py de­signed to curb the pro­duc­tion of the PC­SK9 pro­tein at its source in the liv­er to oust LDL-C from the blood­stream. The Med­i­cines Co part­nered with RNAi pi­o­neer Al­ny­lam to de­vel­op the drug.

Now, an­a­lysts ex­pect the twice-year­ly (more con­ve­nient, and like­ly cheap­er if ap­proved) in­clisir­an to take a chunk out of once-month­ly PC­SK9 mon­o­clon­al an­ti­body sales and reap the block­buster re­turns that the an­ti­bod­ies were orig­i­nal­ly pro­ject­ed to rake in. A Eu­ro­pean mar­ket­ing ap­pli­ca­tion for in­clisir­an is ex­pect­ed to be sub­mit­ted this year.

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 142
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...